Top

BMC Cancer

Published in:

Open Access 01-12-2022 | Acute Myeloid Leukemia | Research

Circulating lnc-LOC as a novel noninvasive biomarker in the treatment surveillance of acute promyelocytic leukaemia

Authors: Guiran Wang, Guiling Yan, Kanru Sang, Huijie Yang, Ni Sun, Yuanyuan Bai, Feng Xu, Xiaoqun Zheng, Zhanguo Chen

Published in: BMC Cancer | Issue 1/2022

Abstract

Background

Acute promyelocytic leukaemia (APL) is a unique subtype of acute myeloid leukaemia (AML) characterized by haematopoietic failure caused by the accumulation of abnormal promyelocytic cells in bone marrow (BM). However, indispensable BM biopsy frequently afflicts patients in leukaemia surveillance, which increases the burden on patients and reduces compliance. This study aimed to explore whether the novel circulating long noncoding RNA LOC100506453 (lnc-LOC) could be a target in diagnosis, assess the treatment response and supervise the minimal residual disease (MRD) of APL, thereby blazing a trail in noninvasive lncRNA biomarkers of APL.

Methods

Our study comprised 100 patients (40 with APL and 60 with non-APL AML) and 60 healthy donors. BM and peripheral blood (PB) sample collection was accomplished from APL patients at diagnosis and postinduction. Quantitative real-time PCR (qRT–PCR) was conducted to evaluate lnc-LOC expression. A receiver operating characteristic (ROC) analysis was implemented to analyse the value of lnc-LOC in the diagnosis of APL and treatment monitoring. For statistical analysis, the Mann–Whitney U test, a t test, and Spearman’s rank correlation test were utilized.

Results

Our results showed that BM lnc-LOC expression was significantly different between APL and healthy donors and non-APL AML. lnc-LOC was drastically downregulated in APL patients’ BM after undergoing induction therapy. Lnc-LOC was upregulated in APL cell lines and downregulated after all-trans retinoic acid (ATRA)-induced myeloid differentiation, preliminarily verifying that lnc-LOC has the potential to be considered a treatment monitoring biomarker. PB lnc-LOC was positively correlated with BM lnc-LOC in APL patients, non-APL AML patients and healthy donors and decreased sharply after complete remission (CR). However, upregulated lnc-LOC was manifested in relapsed-refractory patients. A positive correlation was revealed between PB lnc-LOC and PML-RARα transcript levels in BM samples. Furthermore, we observed a positive correlation between PB lnc-LOC and BM lnc-LOC expression in APL patients, suggesting that lnc-LOC can be utilized as a noninvasive biomarker for MRD surveillance.

Conclusions

Our study demonstrated that PB lnc-LOC might serve as a novel noninvasive biomarker in the treatment surveillance of APL, and it innovated the investigation and application of newly found lncRNAs in APL noninvasive biomarkers used in diagnosis and detection.

Available only for authorised users

Kayser S, Schlenk RF, Platzbecker U. Management of patients with acute promyelocytic leukemia. Leukemia. 2018;32(6):1277–94. https://doi.org/10.1038/s41375-018-0139-4.CrossRefPubMed

de The H, Pandolfi PP, Chen Z. Acute Promyelocytic leukemia: a paradigm for Oncoprotein-targeted cure. Cancer Cell. 2017;32(5):552–60. https://doi.org/10.1016/j.ccell.2017.10.002.CrossRefPubMed

Pollyea DA, Bixby D, Perl A, Bhatt VR, Altman JK, Appelbaum FR, et al. NCCN Guidelines Insights: Acute Myeloid Leukemia, Version 2.2021. J Natl Compr Cancer Netw. 2021;19(1):16–27. https://doi.org/10.6004/jnccn.2021.0002.CrossRef

Gabert J, Beillard E, van der Velden VH, Bi W, Grimwade D, Pallisgaard N, et al. Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe against Cancer program. Leukemia. 2003;17(12):2318–57. https://doi.org/10.1038/sj.leu.2403135.CrossRefPubMed

Ganzel C, Douer D, Tallman MS. Postconsolidation maintenance and monitoring in patients with acute promyelocytic leukemia. J Natl Compr Cancer Netw. 2013;11(12):1512–21. https://doi.org/10.6004/jnccn.2013.0178.CrossRef

Tobal K, Moore H, Macheta M, Yin JA. Monitoring minimal residual disease and predicting relapse in APL by quantitating PML-RARalpha transcripts with a sensitive competitive RT-PCR method. Leukemia. 2001;15(7):1060–5. https://doi.org/10.1038/sj.leu.2402170.CrossRefPubMed

Juul-Dam KL, Ommen HB, Nyvold CG, Walter C, Valerhaugen H, Kairisto V, et al. Measurable residual disease assessment by qPCR in peripheral blood is an informative tool for disease surveillance in childhood acute myeloid leukaemia. Br J Haematol. 2020;190(2):198–208. https://doi.org/10.1111/bjh.16560.CrossRefPubMed

Fernandez-Mercado M, Manterola L, Larrea E, Goicoechea I, Arestin M, Armesto M, et al. The circulating transcriptome as a source of non-invasive cancer biomarkers: concepts and controversies of non-coding and coding RNA in body fluids. J Cell Mol Med. 2015;19(10):2307–23. https://doi.org/10.1111/jcmm.12625.CrossRefPubMedPubMedCentral

Plaks V, Koopman CD, Werb Z. Cancer. Circulating tumor cells. Science. 2013;341(6151):1186–8. https://doi.org/10.1126/science.1235226.CrossRefPubMed

10.

Ko BS, Wang YF, Li JL, Li CC, Weng PF, Hsu SC, et al. Clinically validated machine learning algorithm for detecting residual diseases with multicolor flow cytometry analysis in acute myeloid leukemia and myelodysplastic syndrome. EBioMedicine. 2018;37:91–100. https://doi.org/10.1016/j.ebiom.2018.10.042.CrossRefPubMedPubMedCentral

11.

Quinn JJ, Chang HY. Unique features of long non-coding RNA biogenesis and function. Nat Rev Genet. 2016;17(1):47–62. https://doi.org/10.1038/nrg.2015.10.CrossRefPubMed

12.

Cao M, Zhao J, Hu G. Genome-wide methods for investigating long noncoding RNAs. Biomed Pharmacother. 2019;111:395–401. https://doi.org/10.1016/j.biopha.2018.12.078.CrossRefPubMed

13.

Qi P, Zhou X, Du X. Circulating long non-coding RNAs in cancer: current status and future perspectives. Mol Cancer. 2016;15(1):39. https://doi.org/10.1186/s12943-016-0524-4.CrossRefPubMedPubMedCentral

14.

Xie Y, Zhang Y, Du L, Jiang X, Yan S, Duan W, et al. Circulating long noncoding RNA act as potential novel biomarkers for diagnosis and prognosis of non-small cell lung cancer. Mol Oncol. 2018;12(5):648–58. https://doi.org/10.1002/1878-0261.12188.CrossRefPubMedPubMedCentral

15.

He Z, Qin X, Zhang X, Yi J, Han J. Long noncoding RNA GIHCG is a potential diagnostic and prognostic biomarker and therapeutic target for renal cell carcinoma. Eur Rev Med Pharmacol Sci. 2018;22(1):46–54. https://doi.org/10.26355/eurrev_201801_14099.CrossRefPubMed

16.

Zeng C, Xu Y, Xu L, Yu X, Cheng J, Yang L, et al. Inhibition of long non-coding RNA NEAT1 impairs myeloid differentiation in acute promyelocytic leukemia cells. BMC Cancer. 2014;14:693. https://doi.org/10.1186/1471-2407-14-693.CrossRefPubMedPubMedCentral

17.

Wei S, Zhao M, Wang X, Li Y, Wang K. PU.1 controls the expression of long noncoding RNA HOTAIRM1 during granulocytic differentiation. J Hematol Oncol. 2016;9(1):44. https://doi.org/10.1186/s13045-016-0274-1.CrossRefPubMedPubMedCentral

18.

Chen ZH, Wang WT, Huang W, Fang K, Sun YM, Liu SR, et al. The lncRNA HOTAIRM1 regulates the degradation of PML-RARA oncoprotein and myeloid cell differentiation by enhancing the autophagy pathway. Cell Death Differ. 2017;24(2):212–24. https://doi.org/10.1038/cdd.2016.111.CrossRefPubMed

19.

Yu J, Guo XL, Bai YY, Yang JJ, Zheng XQ, Ruan JC, et al. Genomewide profiling of lncRNA expression patterns in patients with acute promyelocytic leukemia with differentiation therapy. Oncol Rep. 2018;40(3):1601–13. https://doi.org/10.3892/or.2018.6521.CrossRefPubMed

20.

Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391–405. https://doi.org/10.1182/blood-2016-03-643544.CrossRefPubMed

21.

DeAngelo DJ. Tailored approaches to induction therapy for acute Promyelocytic leukemia. J Clin Oncol. 2017;35(6):583–6. https://doi.org/10.1200/JCO.2016.68.4761.CrossRefPubMed

22.

Rio DC, Ares M Jr, Hannon GJ, Nilsen TW. Purification of RNA using TRIzol (TRI reagent). Cold Spring Harb Protoc. 2010;2010(6):pdb prot5439. https://doi.org/10.1101/pdb.prot5439.CrossRefPubMed

23.

Chen Z, Tong Y, Li Y, Gao Q, Wang Q, Fu C, et al. Development and validation of a 3-Plex RT-qPCR assay for the simultaneous detection and quantitation of the three PML-RARa fusion transcripts in acute promyelocytic leukemia. PLoS One. 2015;10(3):e0122530. https://doi.org/10.1371/journal.pone.0122530.CrossRefPubMedPubMedCentral

24.

Beillard E, Pallisgaard N, van der Velden VH, Bi W, Dee R, van der Schoot E, et al. Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using 'real-time' quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) - a Europe against cancer program. Leukemia. 2003;17(12):2474–86. https://doi.org/10.1038/sj.leu.2403136.CrossRefPubMed

25.

Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods. 2001;25(4):402–8. https://doi.org/10.1006/meth.2001.1262.CrossRefPubMed

26.

Spinelli O, Rambaldi A, Rigo F, Zanghì P, D'Agostini E, Amicarelli G, et al. Simple, rapid and accurate molecular diagnosis of acute promyelocytic leukemia by loop mediated amplification technology. Oncoscience. 2015;2(1):50–8. https://doi.org/10.18632/oncoscience.114.CrossRefPubMed

27.

Fu Y, Zhang Y, Khoo BL. Liquid biopsy technologies for hematological diseases. Med Res Rev. 2021;41(1):246–74. https://doi.org/10.1002/med.21731.CrossRefPubMed

28.

Pantel K, Alix-Panabieres C. Liquid biopsy and minimal residual disease - latest advances and implications for cure. Nat Rev Clin Oncol. 2019;16(7):409–24. https://doi.org/10.1038/s41571-019-0187-3.CrossRefPubMed

29.

Jiang S, Cheng SJ, Ren LC, Wang Q, Kang YJ, Ding Y, et al. An expanded landscape of human long noncoding RNA. Nucleic Acids Res. 2019;47(15):7842–56. https://doi.org/10.1093/nar/gkz621.CrossRefPubMedPubMedCentral

30.

Saus E, Brunet-Vega A, Iraola-Guzman S, Pegueroles C, Gabaldon T, Pericay C. Long non-coding RNAs as potential novel prognostic biomarkers in colorectal Cancer. Front Genet. 2016;7:54. https://doi.org/10.3389/fgene.2016.00054.CrossRefPubMedPubMedCentral

31.

Shang C, Guo Y, Zhang H, Xue YX. Long noncoding RNA HOTAIR is a prognostic biomarker and inhibits chemosensitivity to doxorubicin in bladder transitional cell carcinoma. Cancer Chemother Pharmacol. 2016;77(3):507–13. https://doi.org/10.1007/s00280-016-2964-3.CrossRefPubMed

32.

Heid C, Stevens J, Livak K, Williams P. Real time quantitative PCR. Genome Res. 1996;6(10):986–94. https://doi.org/10.1101/gr.6.10.986.CrossRefPubMed

33.

Mousavi-Nasab SD, Azhdar Z, Ghaderi M. Optimization of RT-qPCR for detection of Aichi virus in sewage and river water samples in Karaj, Iran. Arch Iran Med. 2019;55(5):242–6.

34.

Grimwade D, Jovanovic JV, Hills RK, Nugent EA, Patel Y, Flora R, et al. Prospective minimal residual disease monitoring to predict relapse of acute promyelocytic leukemia and to direct pre-emptive arsenic trioxide therapy. J Clin Oncol. 2009;27(22):3650–8. https://doi.org/10.1200/JCO.2008.20.1533.CrossRefPubMed

35.

Sanz MA, Fenaux P, Tallman MS, Estey EH, Lowenberg B, Naoe T, et al. Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet. Blood. 2019;133(15):1630–43. https://doi.org/10.1182/blood-2019-01-894980.CrossRefPubMedPubMedCentral

36.

Bai Y, Chen C, Guo X, Ding T, Yang X, Yu J, et al. miR-638 in circulating leukaemia cells as a non-invasive biomarker in diagnosis, treatment response and MRD surveillance of acute promyelocytic leukaemia. Cancer Biomark. 2020;29(1):125–37. https://doi.org/10.3233/CBM-190899.CrossRefPubMed

37.

Wang H, Peng R, Wang J, Qin Z, Xue L. Circulating microRNAs as potential cancer biomarkers: the advantage and disadvantage. Clin Epigenetics. 2018;10:59. https://doi.org/10.1186/s13148-018-0492-1.CrossRefPubMedPubMedCentral

Title: Circulating lnc-LOC as a novel noninvasive biomarker in the treatment surveillance of acute promyelocytic leukaemia
Authors: Guiran Wang
Guiling Yan
Kanru Sang
Huijie Yang
Ni Sun
Yuanyuan Bai
Feng Xu
Xiaoqun Zheng
Zhanguo Chen
Publication date: 01-12-2022
Publisher: BioMed Central
Keywords: Acute Myeloid Leukemia
Biomarkers
Leukemia
Published in: BMC Cancer / Issue 1/2022
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/s12885-022-09621-1

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2022

Expressional variations of Kaiso: an association with pathological characteristics and field cancerization of OSCC

Correction: Psychotropic and anti-epileptic drug use, before and after surgery, among patients with low-grade glioma: a nationwide matched cohort study

Is RDW a clinically relevant prognostic factor for newly diagnosed multiple myeloma? A systematic review and meta-analysis

Performance of Sonoelastography for predicting malignancy in soft tissue

Management of early-stage triple-negative breast cancer: recommendations of a panel of experts from the Brazilian Society of Mastology

Irregular delay of adjuvant chemotherapy correlated with poor outcome in stage II-III colorectal cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer